medicaldaily.com
Cure8 news brief
Why This Matters
This gives families and clinicians a non‑TNF biologic option on‑label for children aged 2+ with moderate‑to‑severe ulcerative colitis, which can change insurance conversations and expand treatment choices for kids who don’t respond to or lose response to anti‑TNF drugs.
Who Should Pay Attention
Parents and caregivers of children (age 2+) with moderate‑to‑severe ulcerative colitis, pediatric gastroenterologists, and families navigating insurance prior authorization or biologic access.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
The FDA granted a labeled pediatric indication for ustekinumab—meaning clinicians can now prescribe an on‑label IL‑12/23 inhibitor for children with moderately to severely active UC starting at age 2.
The pediatric approval drew on extrapolated adult efficacy plus pediatric safety/pharmacokinetic data and a 52‑week pediatric trial; that trial reported outcomes for the subgroup who responded to induction and had no placebo comparison.
Practical implications: A labeled pediatric indication can strengthen insurance appeals and prior‑authorization requests but does not guarantee coverage; families should confirm plan requirements (e.g., whether prior anti‑TNF failure is required, billing as medical vs pharmacy benefit, and preferred product vs biosimilar).
Biosimilars to ustekinumab exist and may affect access and cost. Manufacturer assistance programs and hospital financial counselors can help navigate affordability.
Safety note: Common adverse reactions in the pediatric UC data included upper respiratory infections, headache, abdominal pain, fever, diarrhea and fatigue; serious adverse events were reported in a minority during maintenance.
Keep In Mind
The pediatric approval leaned heavily on adult efficacy data and a pediatric trial without a placebo arm; week‑52 remission figures were reported for the subgroup who responded to induction. A labeled indication helps with coverage arguments but does not eliminate prior authorization, step therapy, or specialty pharmacy hurdles.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationmedicaldaily.com
PublisherMedical Daily
AuthorsCole Mercer
Indexed viaGoogle News
Source typeWeb article
PublishedSep 2, 2026, 2:01 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Interchangeability Designation for Teva and Alvotech’s Stelara Biosimilar Selarsdi for Multiple Indications
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
Johnson & Johnson's Tremfya recommended by CHMP to treat Crohn's disease - PMLiVE
A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...